BCL2 and neoplasm: Consistent with these findings, our in vitro ADCC assays demonstrated that combining 22.0405.aF with either ibrutinib or venetoclax enhanced tumor cell killing, supporting the rationale for future combination therapy approaches integrating 22.0405.aF with BTK or BCL-2 inhibitors.